Keywords: Peptide Therapy, Insulin-Like Growth Factor-1 (IGF-1), Oncogenesis, GLP-1 Receptor Agonist (GLP-1 RA), Sarcopenia, BPC-157
Introduction
Over the past decade, peptides have ascended from the domain of academic endocrinology to the forefront of consumer health culture. Promoted by high-profile biohackers, longevity advocates, and wellness influencers, peptide compounds are now widely self-administered for an array of goals: accelerating tissue repair, optimizing body composition, boosting cognitive performance, and extending health span. The allure of peptides rests on a superficially compelling premise, they are endogenous signaling molecules, naturally produced by the body, and therefore presumed to be safe.
This cultural framing was most publicly crystallized by entrepreneur and longevity experimenter Bryan Johnson, who cautioned in April 2026 that “people mistakenly believe peptides are only good, but actually can be bad,” warning that indiscriminate peptide use without systematic measurement and medical oversight is fundamentally antithetical to evidence-based health optimization. Johnson’s own experimental trajectory, which included careful, measured trials of BPC-157 and Cerebrolysin, and a deliberate move away from systemic peptides toward topical formulations reflects a maturation of thinking that the broader longevity community has yet to fully adopt [1].
The scientific literature paints a more complicated picture. Peptides are not monolithic in their biology. Their effects are cell-type specific, dose-dependent, context-dependent, and shaped by the individual’s baseline physiology and pre-existing pathology. Growing evidence indicates that certain peptide interventions can drive oncogenic processes, worsen metabolic parameters, deplete skeletal muscle, provoke autoimmune cascades, and cause harm through contamination from poorly regulated supply chains [2,3].
This review does not seek to condemn peptide therapy wholesale. Rather, it aims to provide clinicians and researchers in longevity, prevention, and metabolic medicine with a rigorous synthesis of the evidence for peptide-associated harms, and to argue for a precision-medicine approach that matches the complexity of the biology involved.
Defining the Landscape: What are Peptides and Why Do They Matter?
Peptides are short chains of amino acids, typically comprising 2 to 50 residues, that function as signaling molecules throughout virtually every physiological system. Unlike conventional small-molecule drugs, peptides operate through receptor-mediated pathways with high specificity, short half-lives, and context-dependent pleiotropic effects.
In the context of longevity and metabolic medicine, the most clinically relevant peptide classes include: (1) growth hormone secretagogues (GHS), such as GHRPs and CJC-1295/ipamorelin combinations, which stimulate pituitary GH release; (2) tissue-protective peptides such as BPC-157, a 15-amino acid synthetic peptide derived from gastric juice proteins; (3) GLP-1 receptor agonists, including semaglutide and tirzepatide, now among the most prescribed drugs globally; (4) antimicrobial peptides (AMPs), explored for both infection management and immune modulation; and (5) epigenetic and cognitive peptides such as epithalon and Cerebrolysin.
The appeal of peptides to longevity practitioners is understandable. They engage pathways central to ageing biology such as mTOR signaling, GH/IGF-1 axis, inflammation, and tissue remodeling. However, these same pathways are also central to disease pathogenesis, and their pharmacological activation carries inherent dual-use risks [4].
The Growth Hormone-Releasing Peptide Paradox: IGF-1 as a Double-Edged Signal
Among the most widely used peptide interventions in anti-ageing medicine are GHRPs, including GHRP-2, GHRP-6, ipamorelin, and CJC-1295 which stimulate pituitary secretion of growth hormone (GH) and, consequently, hepatic production of insulin-like growth factor-1 (IGF-1). The rationale is straightforward: GH and IGF-1 decline with age, contributing to sarcopenia, increased adiposity, and reduced tissue regeneration. Restoring youthful levels appears intuitively beneficial [5].
However, the IGF-1 axis operates as one of the most studied longevity paradoxes in biology. Data from the EPIC-Heidelberg cohort study found that circulating IGF-1 above the 75th percentile was significantly associated with elevated risk of cancer-related mortality, cardiovascular events, and all-cause mortality. Persistently elevated IGF-1 broadly defined as above 250–300 ng/mL promotes cellular proliferation, suppresses apoptosis, and has been mechanistically linked to breast, prostate, and colorectal cancers in epidemiological literature [6,7].
The longevity paradox is further illuminated by genetic models. Studies in Laron syndrome, characterized by severe IGF-1 deficiency reveal that affected individuals are remarkably protected from cancer and type 2 diabetes despite short stature, suggesting that chronically elevated IGF-1 carries meaningful oncogenic loading across the lifespan. Conversely, animal experiments and human epidemiological data consistently show that mild downregulation of the insulin/IGF-1 signaling pathway extends lifespan and delays age-related disease in multiple organisms [8,9].
From a pharmacological perspective, CJC-1295 with Drug Affinity Complex (DAC) presents a particularly concerning profile. Its extended half-life maintains supraphysiological GH stimulation for days after a single injection, creating sustained IGF-1 elevation that departs significantly from the pulsatile physiology GH was designed to produce. Long-term clinical data on this intervention are absent. The acknowledged theoretical risks like tumour promotion, insulin resistance, antibody formation remain unquantified in human populations but are mechanistically plausible and clinically non-trivial [10].
Furthermore, GH exerts direct counter-regulatory effects on insulin action via hepatic gluconeogenesis. In patients with pre-existing metabolic syndrome or impaired fasting glucose, precisely the population often seeking longevity interventions, GHRP-driven GH elevation can aggravate insulin resistance, undermining one of the core goals of metabolic medicine [10].
BPC-157 and the Angiogenesis Problem
BPC-157 (Body Protecting Compound-157) has attracted enormous interest in biohacking communities for its apparent tissue-healing, anti-inflammatory, and neuroprotective properties in animal models. Proponents cite studies showing accelerated tendon repair, gut mucosal healing, and neuroprotection following BPC-157 administration in rodent models.
However, the translational leap from rodent data to human clinical practice demands critical scrutiny. As of 2025, there are no completed Phase II or Phase III randomized controlled trials of BPC-157 in humans. The entirety of the biomedical evidence base consists of animal studies and uncontrolled case series [11].
More substantively, a 2025 peer-reviewed commentary published in Pharmaceuticals raised mechanistic concerns about BPC-157’s proangiogenic activity. The compound activates angiogenic signaling pathways, precisely the mechanisms that oncology seeks to suppress with anti-VEGF therapies. Angiogenesis is a fundamental requirement for tumour growth beyond 1–2 mm, and any compound that robustly promotes new vessel formation carries a theoretical risk of accelerating occult or early-stage malignancy [12,13].
The authors of this commentary are careful to note that BPC-157 does not initiate tumorigenesis, it is not directly genotoxic. However, in an individual harboring undetected pre-cancerous lesions or early-stage tumour microenvironments (a scenario not uncommon in mid-life adults), proangiogenic stimulation could represent a meaningful accelerant. The absence of evidence of harm is not evidence of absence, particularly given that the compound has never been studied in humans over intervals sufficient to detect oncological outcomes.
The regulatory position is unambiguous: the U.S. Food and Drug Administration (FDA) has not approved BPC-157 for any human indication and classifies it as an unapproved drug. Its widespread use in peptide compounding facilities, many of which lack quality assurance infrastructure further compounds the risk profile [14].
GLP-1 Receptor Agonists: The Muscle Loss Problem
GLP-1 receptor agonists, particularly semaglutide and tirzepatide, represent a remarkable advance in the pharmacological management of obesity and type 2 diabetes. Their ability to produce substantial, sustained weight loss has rightly generated clinical enthusiasm. However, the composition of that weight loss deserves careful attention from metabolic health practitioners.
Across multiple clinical datasets, GLP-1 RA-induced weight loss is accompanied by a disproportionate reduction in lean body mass, including skeletal muscle relative to fat mass. The SEMALEAN study, a prospective trial enrolling 115 patients with obesity treated with semaglutide 2.4 mg over 12 months, documented significant reductions in appendicular skeletal muscle mass despite apparent improvements in overall body composition metrics. The authors specifically flagged those vulnerable patients like older adults, those with pre-existing low muscle mass, and individuals not engaged in resistance training face meaningful risk of developing iatrogenic sarcopenia [15].
A 2025 systematic review and meta-analysis published in the International Journal of Obesity confirmed that GLP-1 receptor agonist therapy is consistently associated with reductions in lean mass across diverse patient populations, with the ratio of lean-to-fat mass loss varying by drug, dose, and co-intervention status. Given that sarcopenia is itself an independent predictor of metabolic deterioration, cardiovascular risk, functional decline, and all-cause mortality in older adults, the net long-term benefit of GLP-1 therapy in ageing populations warrants careful individual risk stratification [16].
Additional safety signals warrant monitoring. Data from a French national health insurance cohort suggested a 46% increased risk of all thyroid cancers and a 78% increased risk of medullary thyroid cancer among GLP-1 RA users after 1–3 years of exposure. While a subsequent multinational cohort study of 145,000 patients did not replicate this finding, the discordance across large epidemiological datasets reflects residual uncertainty that should inform clinical counselling and post-marketing surveillance [17,18].
Acute pancreatitis has also been reported in association with semaglutide use, and case reports continue to emerge in the post-marketing period. These signals do not negate the profound clinical utility of GLP-1 therapies, but they underscore that even the most rigorously studied peptide-based drugs carry a harm profile that demands informed consent and ongoing monitoring [19].
Antimicrobial Peptides: From Defense to Disease Trigger
Antimicrobial peptides represent a biologically ancient class of host defence molecules with growing interest in therapeutic applications, including infection management, wound care, and immune modulation. However, their mechanism of action, broad disruption of membrane integrity and immune signaling creates inherent non-selectivity that translates to cytotoxicity and immunogenic risk in therapeutic contexts [20].
A systematic review published in the Journal of Translational Medicine (2025) identified immunogenicity, systemic cytotoxicity, and haemolytic activity as the principal barriers to clinical translation of AMPs, noting that the same multi-target mechanism responsible for their broad-spectrum efficacy produces off-target host cellular damage at therapeutic doses [21].
Perhaps most relevant to practitioners in longevity and autoimmune medicine is the documented dual role of endogenous AMPs in autoimmune disease pathogenesis. Research published in Frontiers in Immunology demonstrated that cathelicidins and defensins, the predominant human AMP families can amplify inflammatory cascades by chemoattracting monocytes and other immune effectors, creating a self-reinforcing loop of AMP expression and immune cell infiltration that drives autoimmune tissue damage. The same cathelicidin (LL-37) implicated in psoriasis pathogenesis has simultaneously been shown to have protective effects in type 1 diabetes models, illustrating the profound context-dependency of AMP biology that makes blanket therapeutic generalization scientifically untenable [22].
The Regulatory Vacuum and the Contamination Problem
A dimension of peptide risk that receives insufficient attention in clinical discourse is the quality and regulatory status of the compounds themselves. The vast majority of peptides used in biohacking and longevity contexts such as BPC-157, TB-500, epithalon, DSIP, and growth hormone secretagogues exist outside any approved regulatory framework. They are manufactured by research chemical suppliers or compounding pharmacies operating without pharmaceutical Good Manufacturing Practice (GMP) oversight [14].
FDA testing of commercially available compounded and online-sourced peptides has revealed contamination rates of up to 23% with incorrect active ingredients or undeclared compounds, with up to 40% containing incorrect dosages. DSIP and epithalon have received FDA unapproved new drug designation with associated warning letters, while the Department of Defense’s Operation Supplement Safety classifies BPC-157 as an unapproved drug that cannot be legally prescribed or sold as a consumer supplement in the United States [14,23].
In September 2025, the FDA issued more than 50 warning letters to U.S. and international companies compounding GLP-1 peptides including semaglutide and tirzepatide, reflecting widespread manufacturing non-compliance even in the most commercially prominent peptide drug class. For individuals sourcing peptides from unverified vendors, a common practice in the biohacking community, the compound administered may bear little relationship to what is labelled. Immunogenic reactions, sterile abscesses, systemic infections, and endocrine disruption from adulterants represent real and documented harms [24].
The Biohacker Culture Problem: When Optimism Outpaces Evidence
The cultural ecosystem surrounding biohacking and longevity optimization has created a structurally optimistic bias in how peptide information is disseminated and consumed. Online communities celebrate n-of-1 experimentation, individual anecdote is elevated to near-clinical authority, and the complexity of human physiology is flattened into mechanistic narratives that sound compelling but omit the crucial context of individual variation, baseline pathology, and long-term outcome data.
Bryan Johnson’s 2026 warning is instructive precisely because it comes from within the biohacking tradition rather than from external regulatory critique. Johnson noted that individuals who administer multiple experimental peptides simultaneously lose the ability to attribute outcomes whether it’s a positive or negative to any specific compound, creating epistemic conditions indistinguishable from uncontrolled polypharmacy. His own practice of comprehensive biomarker tracking before, during, and after each peptide trial represents a methodological standard that the community as a whole has not adopted [1].
This matters clinically because the harms of peptide misuse are not uniformly detectable in the short term. IGF-1-driven oncogenesis, progressive sarcopenia from GLP-1 therapy without resistance training, and autoimmune exacerbation from AMP-driven inflammatory amplification may each develop over years, during which the individual continues to attribute subjective performance improvements to their peptide regimen, never connecting compound use to the downstream harm that ultimately manifests.
Toward a Precision Framework for Responsible Peptide Use
None of the evidence reviewed in this paper supports the abandonment of peptide research or the categorical rejection of peptide therapy. GLP-1 receptor agonists have transformed cardiometabolic medicine. Peptide-based wound care is clinically validated. BPC-157 may yet prove useful in specific gastrointestinal indications if subjected to rigorous human trials. The point is precision, not prohibition.
A responsible framework for peptide use in longevity and metabolic medicine should incorporate the following principles. First, comprehensive pre-intervention biomarker assessment is essential, including IGF-1, fasting insulin, HOMA-IR, HbA1c, complete metabolic panel, and age-appropriate cancer screening, before initiating any peptide intervention that activates the GH/IGF-1 axis. Second, muscle mass and function should be monitored longitudinally via DEXA or equivalent body composition assessment throughout GLP-1 RA therapy, with structured resistance training and protein optimization prescribed as co-interventions. Third, only one peptide intervention should be initiated at a time, with sufficient washout periods to permit attribution of outcomes. Fourth, sourcing must be restricted to GMP-certified compounding pharmacies with verified certificate of analysis documentation. Fifth, any individual with a personal or family history of hormone-sensitive malignancy, or with IGF-1 levels in the upper quartile of the reference range, should not receive GHRPs or other IGF-1-elevating compounds outside the context of a clinical trial [6,7,14,15].
Conclusion
The narrative that peptides are universally beneficial is not merely incomplete, it is a clinical and scientific fallacy with real-world harm potential. The same biological properties that make peptides powerful modulators of growth, repair, and immune function also make them capable of driving oncogenesis, metabolic deterioration, muscle wasting, and autoimmune exacerbation under specific conditions. These risks are not hypothetical: they are grounded in mechanistic biology, epidemiological data, clinical trial safety signals, and regulatory enforcement actions.
As the field of longevity and preventive medicine continues to mature, it has a responsibility to resist the optimism bias embedded in consumer health culture. Peptide interventions deserve the same rigorous evidence standards applied to any pharmacological agent like controlled trials, long-term safety surveillance, regulatory oversight, and individualized clinical assessment. The goal of living longer and healthier is shared by clinicians, researchers, and patients alike. That goal is not served by conflating biological plausibility with clinical efficacy, or natural origin with safety.
Peptides are not inherently good. They are not inherently bad. They are complex biological signals operating in complex physiological contexts. Treating them with the precision that complexity demands is both the scientific imperative and the ethical obligation of those working in this field.
Reference
1. Johnson B. Bryan Johnson warns about peptide risks before you start taking them [Internet]. Longevity Today. 2026 Apr 14 [cited 2026 Jun 3]. Available from: https://longevitytoday.com/articles/bryan-johnson-warns-about-peptide-risks-before-you-start-taking-them
2. Józwiak P, Wierzbicki PM, Krasowska-Kwiecień A, Krześlak A. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185.
3. MD Pilot. Peptide safety & side effects 2025: latest research, risks and side effects [Internet]. MD Pilot. 2025 [cited 2026 Jun 3]. Available from: https://md-pilot.com/are-peptides-safe-latest-research-risks-and-side-effects-2024-2025/
4. Haigis MC, Yankner BA. The aging stress response. Mol Cell. 2010 Oct 22;40(2):333–44.
5. Biotech Peptides. Pharmacological and metabolic insights into the ipamorelin and CJC-1295 blend [Internet]. 2025 Sep 2 [cited 2026 Jun 3]. Available from: https://biotechpeptides.com/2025/09/02/pharmacological-and-metabolic-insights-into-the-ipamorelin-cjc-1295-blend/
6. Björk S, Heikkinen A, Ollikainen M, Pietiläinen KH, Mikkola TM, Tikkanen E, et al. IGF-1 and risk of morbidity and mortality from cancer, cardiovascular diseases, and all causes in EPIC-Heidelberg. J Clin Endocrinol Metab. 2023;108(10):e1092–e1104.
7. Fuhrman J. IGF-1: the hidden hormone that fuels cancer and how to lower it naturally [Internet]. DrFuhrman.com. 2024 [cited 2026 Jun 3]. Available from: https://www.drfuhrman.com/blog/297/igf-1-the-hidden-hormone-that-fuels-cancer-and-how-to-lower-it-naturally
8. Navarro I, Shim YH, Boosani CS. Insulin-like growth factors and aging: lessons from Laron syndrome. Front Endocrinol (Lausanne). 2023;14:1291812.
9. Holzenberger M, Dupont J, Ducos B, Leneuve P, Géloën A, Even PC, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003;421(6919):182–7.
10. Nationwide Peptides. CJC-1295 2026 review: mechanism, uses, safety and FDA status [Internet]. 2026 [cited 2026 Jun 3]. Available from: https://www.nationwidepeptides.com/peptide/cjc-1295-2026-review/
11. MediSearch. Does BPC-157 increase cancer risk? [Internet]. MediSearch. 2024 [cited 2026 Jun 3]. Available from: https://medisearch.io/blog/bpc157-and-cancer-risk
12. Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, et al. BPC 157 therapy: targeting angiogenesis and nitric oxide’s cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions. Pharmaceuticals (Basel). 2025;18.
13. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31.
14. PeptideExaminer. The FDA’s war on peptides: a complete 2024–2026 enforcement timeline [Internet]. PeptideExaminer. 2025 [cited 2026 Jun 3]. Available from: https://peptideexaminer.com/articles/fda-peptide-enforcement-2025-guide/
15. Alissou M, Lachekhab C, Amrani C, Benbella A. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab. 2026;28:e70141.
16. Hu X, Wang Q, Zhou X, Chen L, Su Z, Zhu M, et al. GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Obes (Lond). 2026. doi:10.1038/s41366-026-02088-1
17. Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384–90.
18. Htike ZZ, Flatt S, Duval D, Whincup P, Gillies CL, Davies MJ. Efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19(2):228–38.
19. Pham VH, Le HC, Nguyen BL, Tran VT. Acute pancreatitis associated with semaglutide in a patient with multimorbidity: a case report. PMC. 2025; PMC12919507.
20. Antimicrobial peptides: mechanisms, applications, and therapeutic potential. PMC. 2025; PMC12399857.
21. Li J, Koh JJ, Liu S, Lakshminarayanan R, Verma CS, Beuerman RW. Membrane active antimicrobial peptides: translating mechanistic insights to design. Front Neurosci. 2017;11:73. [Updated data from: Antimicrobial peptide biological activity, delivery systems and clinical translation status and challenges. J Transl Med. 2025;23(1):1–30.]
22. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19. [Supplemented by: The dual role of antimicrobial peptides in autoimmunity. Front Immunol. 2020;11:2077.]
23. Holt Law. The unregulated world of peptides: what you need to know before you inject [Internet]. Holt Law. 2025 [cited 2026 Jun 3]. Available from: https://djholtlaw.com/the-unregulated-world-of-peptides-what-you-need-to-know-before-you-inject/
24. Wilson Sonsini. FDA sends warning letters to more than 50 GLP-1 compounders and manufacturers [Internet]. Wilson Sonsini. 2025 Sep [cited 2026 Jun 3]. Available from: https://www.wsgr.com/en/insights/fda-sends-warning-letters-to-more-than-50-glp-1-compounders-and-manufacturers.html